Sulfotransferase: A Promising Protein for Drug Development (P45931)

Target Name: Sulfotransferase

NCBI ID: P45931

Sulfotransferase

Other Name(s): SULT

Sulfotransferase: A Promising Protein for Drug Development

Sulfotransferase (SULT) is a gene that encodes a protein known as SULT, which is a key enzyme in the transfer of sulfur groups from one molecule to another. Sulfur transfer reactions are essential for a wide range of biological processes, including the regulation of enzyme activity and the detoxification of harmful substances.

SULT has four known subtypes, which are nonspecific subtypes (SULT1, SULT2, SULT3, and SULT4). These subtypes are different in their catalytic specificity and substrate requirements, but all of them share a common catalytic core.

SULT1 is the most abundant subtype, and it is involved in a wide range of cellular processes, including the transfer of sulfur groups to other molecules. SULT1 is also the best understood, and many studies have focused on its catalytic properties and its potential as a drug target.

One of the key features of SULT1 is its ability to transfer sulfur groups to a wide range of substrates, including small molecules, peptides, and even proteins. This ability makes SULT1 a promising target for drugs that want to modulate cellular processes and introduce new functions.

Another promising aspect of SULT1 is its ability to activate multiple downstream targets of various signaling pathways. This suggests that SULT1 may play a key role in the regulation of cellular processes that are responsive to multiple signaling pathways.

SULT2 is the second most abundant subtype of SULT and is involved in the transfer of sulfur groups to small molecules and peptides. SULT2 has been shown to play a role in the regulation of cellular processes that are dependent on sulfur transfer, including the detoxification of xenobiotics and the regulation of inflammation.

SULT3 is the third most abundant subtype of SULT and is involved in the transfer of sulfur groups to small molecules and peptides. SULT3 has been shown to play a role in the regulation of cellular processes that are dependent on sulfur transfer, including the detoxification of xenobiotics and the regulation of inflammation.

SULT4 is the least abundant subtype of SULT and is involved in the transfer of sulfur groups to small molecules and peptides. SULT4 has been shown to play a role in the regulation of cellular processes that are dependent on sulfur transfer, including the detoxification of xenobiotics and the regulation of inflammation.

Despite its promising role in cellular processes, SULT has not yet been shown to be a drug target. Many studies have focused on its catalytic properties and its potential as a drug target, but more research is needed to determine its full potential as a therapeutic agent.

In conclusion, Sulfotransferase (SULT) is a gene that encodes a protein involved in the transfer of sulfur groups from one molecule to another. SULT has four known subtypes, which are nonspecific subtypes (SULT1, SULT2, SULT3, and SULT4). SULT1 is the most abundant and has been shown to be involved in a wide range of cellular processes, including the transfer of sulfur groups to other molecules. Its ability to transfer sulfur groups to multiple substrates and its potential as a drug target make SULT an attractive target for the development of new therapeutic agents. Further research is needed to fully understand its functions and potential as a therapeutic agent.

Protein Name: Sulfotransferase (nonspecified Subtype)

The "Sulfotransferase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Sulfotransferase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets